D
dnrheightpill
Banned
- Joined
- Apr 3, 2026
- Posts
- 2
- Reputation
- 11
THE ONLY SCIENTIFICALLY VALID HEIGHT MAXX THREAD YOU NEED [FULL PROTOCOL + DEBATES + MECHANISMS]
I'm going to write the actual definitive thread on height optimization. Not the stuff you find on here about "take mk677 bro." I mean the real mechanistic stack, grounded in growth plate biology. 99% of you are either running nothing, running things that actively work against you, or running the right things in the wrong order. I'll address the common arguments directly with verdicts.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
I. WHY IGF-1 LR3 AND INCRELEX ARE COPE FOR HEIGHT
This is the most common mistake I see. Someone runs 200mcg IGF-1 LR3 a day thinking they're doing something for height. They're not.
The Core Problem:
Exogenous IGF-1 without GH's independent effects pushes chondrocytes straight into hypertrophic differentiation. The plate thickens but doesn't elongate. You're not growing, you're accelerating ossification.
The growth plate has two distinct cell populations: resting zone progenitors (gpSSCs) and proliferative zone chondrocytes. GH acts on BOTH. Here is the critical mechanism most people don't know:
Dual Effector Theory (Green et al.):
GH has a DIRECT effect on resting zone stem cell recruitment, independent of IGF-1. It's not just "GH makes the liver produce IGF-1." GH also directly binds GHRs on resting zone progenitors and drives them into the proliferative pool. This is the effect that pure exogenous IGF-1 cannot replicate.
When you inject IGF-1 LR3 without this upstream GHR activation:
- IGF-1R on chondrocytes gets saturated and drives cells toward hypertrophic differentiation
- Hypertrophic chondrocytes expand 5-10x in volume, mineralize, die, and get replaced by bone
- The plate appears active on MRI but you're burning through your chondrocyte reserve faster
- Longitudinal growth requires: GH direct resting zone activation + IGF-1 proliferative expansion + controlled hypertrophy
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
II. GH: THE MASTER PATHWAY
GH is non-negotiable. It's the central axis everything else plugs into. But there's nuance that most people running GH still miss.
The IGF-1 Saturation Ceiling is Real:
Hepatic GH receptors saturate around 8-12 IU for most people. Past that dose you're not getting meaningfully more IGF-1. You're getting insulin resistance, joint compression from water retention, mTOR-driven chondrocyte senescence, and cortisol dysregulation. None of which you want.
The mTOR point is the most important thing most GH-brained people miss. Very high IGF-1 signaling activates mTOR which pushes cells toward differentiation rather than self-renewal. You're simultaneously running compounds to maintain stem cell stemness while chronically supraphysiological IGF-1 works against them. 8 IU is the rational sweet spot.
Tresiba (Basal Insulin) dramatically amplifies your GH response.
Insulin upregulates hepatic GH receptor expression. So the same 8 IU GH produces significantly more IGF-1 when paired with basal insulin coverage. Tresiba also hits IGF-1R at the growth plate directly. Not just glucose management. A synergistic anabolic on your chondrocytes.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
III. FGFR3 INHIBITORS: REMOVING THE BRAKE
FGFR3 is the endogenous brake on chondrocyte proliferation. Gain-of-function mutations cause achondroplasia. Even wildtype FGFR3 exerts tonic inhibition on the proliferative zone. You want to suppress it.
1. TYRA-300 [S TIER]
Highly selective oral FGFR3 inhibitor, Phase II. Best oral bioavailability. Grey market accessible. Purpose-built to suppress FGFR3 with minimal FGFR1/2 bleedthrough.
2. LOXO-435 (LY3866288) [S TIER]
361-fold selectivity for FGFR3 over FGFR1. The most selective FGFR3 inhibitor that exists. Wildtype FGFR3 inhibition requires a fraction of the oncologic dose, estimated 10-30mg/day. No serious AE profile at low dose.
3. Navepegritide [A TIER]
CNP analog. Works via NPR-B independently of FGFR3, while also downregulating FGFR3-MAPK signaling. FDA approved 2026. Prescription only. The independent anabolic arm via NPR-B is fully functional in non-ACH individuals.
4. Vosoritide (BMN-111) [A TIER]
Earlier generation CNP analog. Same mechanism as navepegritide, daily SC vs weekly. Has appeared in grey markets.
5. Infigratinib [B TIER]
Oral pan-FGFR inhibitor with FGFR3 preference. Less selective than TYRA-300 or LOXO-435. Real FGFR1/2 off-target risk. Accessible.
6. Erdafitinib [B TIER]
Pan-FGFR inhibitor. Accessible but significant FGFR1-mediated hyperphosphatemia at therapeutic doses. Last resort.
Stacking FGFR3 inhibitors with CNP analogs:
They work at different nodes. TYRA-300/LOXO-435 block FGFR3 at the receptor (kinase inhibition). CNP analogs drive positive chondrocyte signaling through NPR-B independently AND suppress FGFR3-MAPK from downstream. Complementary, not redundant.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
IV. SERDs AND AIs: THE ESTROGEN STRATEGY
E2 has a dose-dependent dual role at the growth plate:
- Low E2: stimulates proliferative zone via both ERα and ERβ
- High E2: accelerates hypertrophic differentiation and drives fusion via ERα
- ERα is the fusion receptor. ERβ is the proliferation/survival receptor.
Fulvestrant (500mg/14 days):
Pure pan-ER degrader. Degrades both ERα and ERβ. Most complete ERα blockade. Growth plate penetration limited (highly lipophilic, 99% protein bound) which is both a limitation and partly a feature.
Camizestrant:
Oral SERD with complete ERα degradation, lower MW improving growth plate cartilage penetration. Mechanistically superior to fulvestrant for this specific application.
Anastrozole (0.5-1mg/day):
Aromatase inhibitor, reduces E2 synthesis upstream. AI + SERD together gives fuller coverage than either alone.
ERβ Protection with S-equol and Isoliquiritigenin:
S-equol has roughly 20x selectivity for ERβ over ERα. If ERβ agonists occupy the binding pocket before fulvestrant binds, ERβ is partially protected from degradation. You get ERα degraded + ERβ partially preserved. This is pharmacologically coherent.
Critical Point on Skeletal Maturation:
Every warning about androgens causing bone age advancement is from studies with normal E2 levels. The skeletal maturation was ERα-mediated, driven by residual E2. With anastrozole + SERD eliminating E2 and degrading ERα, the androgenic stack loses its skeletal maturation risk entirely. The 1963 Laron study on fluoxymesterone shows this directly: growth velocity increased in every treated subject, and bone age advancement was dose and E2 dependent.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
V. KY19382: THREE-NODE WNT COVERAGE
KY19382 is a small molecule that does two things simultaneously:
1. Blocks CXXC5-DVL interaction
CXXC5 gets upregulated during growth plate senescence, triggered by estrogen. It binds DVL to suppress Wnt/β-catenin signaling, resulting in growth plate closure. KY19382 blocks CXXC5 from binding DVL downstream.
2. Inhibits GSK3β
GSK3β phosphorylates β-catenin for degradation. Inhibiting it allows β-catenin to accumulate and activate Wnt target genes including chondroprogenitor expansion.
Three-node Wnt coverage stacked with a SERD:
- Camizestrant blocks estrogen → CXXC5 transcription (upstream)
- KY19382 blocks CXXC5 → DVL binding (downstream)
- KY19382 inhibits GSK3β → activates β-catenin (independent of CXXC5)
Hitting Wnt/β-catenin suppression at three completely separate nodes simultaneously.
KY19382 Dosing Note:
Mouse study: 0.1mg/kg IP. HED for 58kg = 0.47mg/day IP equivalent. Oral bioavailability is 16.74%, so oral dose needed = approximately 2.8mg/day. Running 6mg oral ED gives an effective absorbed dose of ~1mg, roughly 2x the mouse-equivalent. Probably fine given the compound's safety profile in the study, but start at 3mg and titrate.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
VI. ABALOPARATIDE: THE PTHrP AXIS
Abaloparatide is a synthetic 34-aa analog of PTHrP(1-34). It binds the RG conformation of PTH1R, driving anabolic signaling with less hypercalcemia than teriparatide due to lower affinity for the R0 conformation that mediates renal calcium reabsorption.
Why it matters for height:
PTHrP is an endogenous signal that keeps growth plate chondrocytes in the proliferative state. It is the downstream effector of the IHH/PTHrP negative feedback loop that governs how fast chondrocytes progress from proliferative to hypertrophic. More PTHrP signaling = chondrocytes stay proliferative longer before committing to hypertrophy.
Abaloparatide does this pharmacologically. The net effect is:
- Delays hypertrophic differentiation, expanding the proliferative pool
- Keeps the plate in a growth-competent state longer
- Directly compensates for the anti-hypertrophy pressure you need to maintain balanced elongation
The balance point abaloparatide helps manage:
Your protocol is heavily anti-hypertrophic by design (mocetinostat, low E2, TYRA-300). The risk is you suppress hypertrophy too completely and the plate thickens without actually producing longitudinal growth. Abaloparatide's role is subtler than just "delays hypertrophy." It maintains PTH1R signaling to keep the feedback loop intact so chondrocytes still eventually progress through hypertrophy in a controlled and orderly manner, just slower. It's a rate modulator, not a complete block.
Dosing and practical notes:
Approved dose for osteoporosis: 80mcg/day SC. For growth plate purposes the dose relationship is not established. Daily SC injection is the limitation. The 2-year black box warning (osteosarcoma risk from rodent studies at high doses) applies, so duration planning matters. Do not skip the 2-year ceiling.
Important: why continuous PTH1R agonism is not ideal
PTH1R desensitizes under continuous stimulation. Internalization and downregulation occur. This is why teriparatide is pulsatile (daily injection for peak/trough) rather than continuous infusion. Abaloparatide's daily SC injection protocol is designed around this intermittent pulsatile mechanism. Do not attempt to run it as continuous infusion chasing "more signal." You will get less effect, not more.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
VII. ANDROGENS: THE NUANCE EVERYONE GETS WRONG
AR signaling at the growth plate = pro-proliferative
ERα signaling at the growth plate = pro-fusion
You can run androgenic compounds in a zero-E2 environment and get the proliferative AR benefit with none of the fusion risk.
Halotestin (Fluoxymesterone) | 5-10mg/day
AR affinity roughly 8-10x testosterone. Does not aromatize. Most potent androgenic oral available. At 5mg, hepatotoxicity concern is dramatically reduced vs the competitive dosing the warnings were written around. With TUDCA/NAC you can extend duration significantly. Delivers the strongest AR-mediated chondrocyte proliferative signal without any E2 conversion risk.
Anavar (Oxandrolone) | 30-50mg/day
Mild DHT derivative. Does not aromatize. Note: at 10mg it contributes essentially nothing meaningful to this stack beyond tissue preservation. The growth plate-relevant dose starts at 30-50mg. If you're already running Halo, Mast, and Primo then Anavar is arguably redundant as a fourth androgen and can be dropped.
Masteron (Drostanolone) | 300-400mg/week
2-alpha methyl DHT. Cannot aromatize. Its anti-estrogenic mechanism is a weak ER antagonist at the receptor level (not primarily an aromatase inhibitor as commonly stated). In a near-zero E2 environment that distinction is irrelevant since there's minimal E2 for it to block anyway. Clean additive androgenic signal.
Primobolan (Methenolone) | 400-600mg/week
Low hepatotoxicity. Moderate AR potency. No aromatization. Immunomodulatory properties. Lowest side effect profile of any injectable androgen. Best choice for long-duration runs where you need sustained androgenic background.
Trenbolone | use with caution on this protocol
Does not aromatize (good for this stack). Strong IGF-1 upregulation, potent anti-catabolic via GR antagonism. However significant progestin activity (60% of progesterone at PR) which complicates the endocrine environment. The neurological side profile including sleep disruption is directly counterproductive on a protocol where natural GH pulsatility and sleep quality matter. Short pulses only, or exclude.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
VIII. FORSKOLIN: THE OVERLOOKED cAMP DRIVER
Forskolin directly activates adenylyl cyclase, elevating intracellular cAMP broadly:
- cAMP is the second messenger for CNP/NPR-B signaling (additive to navepegritide)
- cAMP activates PKA, phosphorylates CREB, upregulates chondrogenic gene expression
- cAMP signaling promotes PTHrP expression and delays hypertrophic differentiation
- Direct synergy with A2B adenosine receptor signaling at the growth plate
Cheap, accessible, hits a node nothing else in the stack directly targets. 25-50mg/day standardized to 10% forskolin.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
IX. DEBATES: WHO WAS CORRECT, WHO WAS WRONG, AND HOW TO USE IT
These are real arguments that have come up in this community. I will give my actual verdict on each with the mechanistic reasoning, and most importantly the practical optimization conclusion.
---
DEBATE 1: "IGF-1 LR3 is equivalent to GH for height"
Verdict: WRONG
The wrong argument: "GH just converts to IGF-1 anyway, so running IGF-1 LR3 directly is more efficient. Same effect, skip the liver step."
Why it's wrong: GH has a direct, IGF-1-independent effect on resting zone gpSSCs via GHR binding on those cells (dual effector theory). Exogenous IGF-1 without this upstream gpSSC recruitment simply saturates IGF-1R on proliferating chondrocytes and pushes them into hypertrophy faster. You're not running out of IGF-1 signal on 8 IU GH. You're running out of the resting zone recruitment signal that IGF-1 LR3 cannot provide.
Optimization conclusion: Run GH at 8 IU. Do not add IGF-1 LR3 or Increlex unless you have a documented reason to believe your IGF-1 levels are low despite adequate GH dose. Get bloodwork. If IGF-1 is mid-range on 8 IU GH, Tresiba (basal insulin) is a far better lever than exogenous IGF-1 because it sensitizes hepatic GH receptors and amplifies your GH-to-IGF-1 conversion without the ossification risk.
---
DEBATE 2: "More GH is always better, just run 30 IU"
Verdict: PARTIALLY CORRECT (with critical conditions)
The argument: "GH has direct effects on resting zone chondrocytes beyond IGF-1. More GH = more direct recruitment. So 30 IU gives growth that 8 IU can't."
Why it's partially correct: True that direct GHR effects on the growth plate continue scaling beyond the IGF-1 saturation point. GH does recruit resting zone cells through a mechanism independent of hepatic IGF-1 output.
Why the conclusion is wrong: At 30 IU you get aggressive insulin resistance that creates a hostile metabolic environment for chondrocytes. Chronic hyperglycemia and hyperinsulinemia impair growth plate function. You also get mTOR hyperactivation which pushes cells toward differentiation rather than self-renewal, directly opposing SAG21k and KY19382. Water retention compresses joint spaces. The cardiovascular load is real. And you're paying 3-4x the cost for marginal direct GHR benefit over 12-16 IU.
Optimization conclusion: 8 IU base with Tresiba amplification is smarter than jumping to 30 IU. If escalating, go to 12-16 IU maximum and manage the insulin resistance aggressively. Never run 30 IU long-term on a growth plate protocol where stem cell self-renewal is a priority.
---
DEBATE 3: "TYRA-300 depletes your resting zone and causes plates to fuse faster"
Verdict: PARTIALLY CORRECT MECHANISM, WRONG CONCLUSION
The argument (forum): Someone reported their plates fused faster after running TYRA-300. Mechanism proposed: FGFR3 inhibition removes the proliferative brake, chondrocytes cycle faster, resting zone gets exhausted sooner, plate closes.
Why the mechanism has biological plausibility: The resting zone pool is finite. Anything accelerating chondrocyte throughput rate theoretically consumes it faster. Not nonsense.
Why the anecdote proves nothing: N=1, no documented baseline plate status, no controlled variables. The rapid fusion observed after stopping TYRA-300 is far more consistent with rebound FGFR3 hyperactivation after removing the inhibitor, which actively promotes terminal differentiation. Stopping abruptly is worse than tapering.
Why the conclusion is still wrong in context: The resting zone depletion risk is real on TYRA-300 alone. It is completely countered by SAG21k (symmetric gpSSC self-renewal), APEX-51B (perichondrial progenitor recruitment into resting zone), and mocetinostat/ricolinostat (extends chondrocyte proliferative lifespan). The correct response to this argument is not to avoid TYRA-300 but to run the full resting zone protection stack alongside it.
Optimization conclusion: Do not run TYRA-300 as a standalone. It is a one piece of a circuit. Pair it with SAG21k for resting zone replenishment and mocetinostat for extending chondrocyte proliferative lifespan. If access to SAG21k is limited, cycle TYRA-300 (8 weeks on, 4 weeks off minimum) rather than running it continuously. Never hard stop. Taper over 2-3 weeks.
---
DEBATE 4: "Androgens cause bone age advancement and will close your plates"
Verdict: WRONG IN THIS CONTEXT
The argument: "Halo/Anavar/Primo all accelerate bone maturation. The prescribing info says so. Don't use androgens for height."
Why it's contextually wrong: Every study that shows androgens accelerating bone age was conducted in subjects with normal E2 physiology. The skeletal maturation effect was ERα-mediated, driven by residual estradiol still circulating and acting on ERα at the growth plate. It was not the androgen doing the fusing, it was the estrogen that the androgen was aromatizing into, or the background estrogen present regardless.
The 1963 Laron fluoxymesterone study is the key reference. Even in those normal-E2 subjects, the growth plate fusion risk was dose-dependent and related to estrogen exposure. Running halo in a zero-E2 environment where anastrozole and fulvestrant have eliminated aromatizable substrate and degraded ERα fundamentally changes the pharmacological context. The prescribing warning simply does not apply.
Optimization conclusion: Run an AI to eliminate E2 production. Run a SERD (camizestrant/fulvestrant) to degrade ERα directly. In that environment, androgenic compounds provide pure AR-mediated proliferative signaling at the growth plate with zero skeletal maturation risk. This is a feature of the complete protocol, not a loophole. Half the protocol is what makes the other half safe.
---
DEBATE 5: "Blocking all estrogen is bad for height because estrogen makes you grow"
Verdict: WRONG (dose-dependent nuance missed)
The argument: "Estrogen promotes chondrocyte proliferation. Blocking it will slow your growth velocity."
Why it's partially true: At low levels, E2 does stimulate proliferative zone activity via both ERα and ERβ. Growth velocity in aromatase-deficient males is maintained but sometimes slightly reduced compared to normal E2. This is real.
Why the conclusion is wrong: At high pubertal levels, E2 drives growth plate fusion via ERα. The question is whether you want the modest proliferative contribution of E2 at the cost of accelerated fusion. The answer is no, because you can replace that proliferative signal with GH, IGF-1, abaloparatide, FGFR3 inhibitors, and SAG21k without the fusion risk. You're not losing anything you can't cover with better tools. You're gaining permanent plate preservation.
Optimization conclusion: The approach is not "block all estrogen." It's "degrade ERα to block fusion while preserving ERβ for chondrocyte survival via S-equol/isoliquiritigenin." The distinction matters. The goal is selective ERα suppression, not total estrogen ablation. Run camizestrant (selective ERα degrader) rather than fulvestrant if possible since fulvestrant is pan-ER.
---
DEBATE 6: "SARMs are better than AAS for this protocol because they don't suppress the HPTA"
Verdict: WRONG
The argument: "Use SARMs for the androgenic signal at the growth plate without suppressing LH/FSH."
Why it's wrong: SARMs still suppress HPTA. AR signaling at the hypothalamus does not care whether the ligand is "tissue-selective" at peripheral tissues. The hypothalamus has AR. RAD140 actually suppresses HPTA more aggressively than Anavar at similar AR occupancy levels because of its potency at hypothalamic AR. The whole "selective" premise was always about muscle vs prostate, not about HPG axis sparing.
Optimization conclusion: Run HCG + HMG throughout the androgenic stack to maintain testicular function and spermatogenesis. This is a far more reliable solution than trying to find an AR agonist that doesn't suppress LH/FSH. The latter doesn't exist at any meaningful dose. Use classical AAS and manage the suppression directly.
---
DEBATE 7: "PHD inhibitors for HIF-1α stabilization but DMOG raises hematocrit"
Verdict: CORRECT CONCERN, WRONG COMPOUND CHOICE
The argument: "PHD inhibition stabilizes HIF-1α in chondrocytes which upregulates glycolytic machinery in the hypoxic growth plate. But DMOG will raise your hematocrit since PHD2 inhibition stabilizes HIF-2α which drives EPO upregulation."
Why the concern is correct: Completely right about DMOG. It's a pan-PHD inhibitor hitting PHD1/2/3. PHD2 is the primary regulator of both HIF-1α in chondrocytes AND HIF-2α systemically. DMOG will raise EPO and hematocrit. This is the same reason roxadustat (a pan-PHD inhibitor) is specifically used to treat CKD anemia. If you want PHD inhibition without the hematocrit issue, you need selectivity.
Optimization conclusion: IOX2 is PHD2-selective with significantly higher preference for PHD2 over PHD1 and PHD3. In chondrocytes, PHD2 is the dominant regulator of HIF-1α. IOX2 stabilizes HIF-1α locally in the growth plate without meaningful HIF-2α/EPO drive. The hematocrit concern largely disappears. IOX2 is what you should be running, not DMOG. DMOG is what roxadustat wishes it wasn't.
---
DEBATE 8: "Blocking all hypertrophy = maximum growth plate preservation = maximum height"
Verdict: WRONG — this is the most dangerous protocol mistake
The argument: More HDAC inhibition, more anti-hypertrophy compounds, lower the hypertrophy rate as far as possible.
Why it's completely wrong: Longitudinal growth is produced by hypertrophic chondrocytes. They expand 5-10x in volume and then get replaced by bone at the metaphyseal front. That replacement is what makes you taller. If you suppress hypertrophy completely, the proliferative zone fills up with non-progressing chondrocytes. The plate thickens on MRI. But you don't grow. You are producing chondrocytes that never differentiate and never contribute to height.
The protocol should slow hypertrophy relative to proliferation. Not stop it.
Optimization conclusion: The lever is mocetinostat dose. Use growth plate MRI as your throttle control:
- Plate getting THICKER over time = proliferation dominant, too little hypertrophy, lower mocetinostat
- Plate STABLE thickness = perfect balance of proliferation and hypertrophic progression, you are actively growing
- Plate getting THINNER = hypertrophy outpacing proliferation, increase mocetinostat
Get MRI every 3-4 months. Adjust mocetinostat dose accordingly. This is not optional if you want to run this protocol seriously.
---
DEBATE 9: "Masteron inhibits aromatase, that's its anti-estrogenic mechanism"
Verdict: PARTIALLY WRONG (someone actually corrected this correctly)
The argument initially: Masteron inhibits aromatase activity, reducing E2 production.
The correction (which was right): Masteron's primary anti-estrogenic mechanism is acting as a weak competitive antagonist at the estrogen receptor, not via meaningful aromatase inhibition. It doesn't significantly reduce aromatase enzyme activity. It competes with E2 at ERα binding sites, blunting transcriptional response without fully activating the receptor.
Why it doesn't change masteron's role in this protocol: In a near-zero E2 environment with anastrozole + SERD coverage, there's essentially nothing for masteron to antagonize at ERα anyway. The ERα receptors are being degraded by fulvestrant/camizestrant. Masteron's value in this stack is purely androgenic signaling through AR, not its anti-estrogenic effect. The mechanism debate is interesting but operationally irrelevant here.
Optimization conclusion: Don't use masteron for E2 control. You have an AI and a SERD for that. Use masteron for its clean non-aromatizing androgenic signal and nothing else.
---
DEBATE 10: "T3 will accelerate height gain by driving hypertrophic zone progression"
Verdict: WRONG FOR THIS PROTOCOL
The argument: T3 directly drives hypertrophic zone differentiation which is rate-limiting for longitudinal growth. Therefore T3 should accelerate height gain.
Why it's wrong for this specific protocol: T3 accelerates hypertrophic differentiation, burning through the proliferative pool faster. On a protocol that is already carefully managing the proliferation/hypertrophy balance, adding T3 tilts the ratio in the wrong direction. You end up consuming your chondrocyte reserve faster without a proportional benefit since you're already driving elongation via GH/IGF-1/abaloparatide. The net effect is shorter runway.
Optimization conclusion: Drop T3 from this protocol entirely. Thyroid function should be kept euthyroid, not pushed toward accelerated differentiation. If you have subclinical hypothyroidism, correct it to normal range. Do not run supraphysiological T3 while trying to maintain resting zone progenitor supply.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
X. COMPLETE STACK SUMMARY
TIER 1 (NON-NEGOTIABLE CORE):
- GH: 8 IU/day split dosing, pre-bed emphasis
- TYRA-300: selective FGFR3 inhibitor, removes proliferative brake
- Fulvestrant or Camizestrant: ERα degradation, blocks plate fusion signal
- Anastrozole: upstream E2 suppression complementing SERD
- KY19382: Wnt/β-catenin activation at three nodes (3mg start, titrate to 6mg oral)
- Abaloparatide: 80mcg/day SC, PTHrP axis activation, keeps chondrocytes proliferative, balances hypertrophic progression
- SAG21k: Smoothened agonist, IHH pathway, gpSSC symmetric self-renewal
- Tresiba (basal insulin): amplifies GH-to-IGF-1 conversion, direct chondrocyte anabolism
TIER 2 (HIGH VALUE ADDITIONS):
- Navepegritide or Vosoritide: CNP analog, NPR-B agonism, stacks with FGFR3 inhibitor
- LOXO-435: if accessible, stack with TYRA-300 for dual-node FGFR3 suppression
- Mocetinostat: HDAC1/2/3 inhibitor, SOX9 upregulation. HDAC4 MUST BE SPARED. Dose titrated against MRI thickness feedback
- Ricolinostat: HDAC6 inhibitor, primary cilia function, potentiates SAG21k
- Halotestin: 5-10mg/day, highest AR potency, zero aromatization
- Primobolan: long-duration clean androgenic base
- Masteron: additive androgenic signal, weak ER antagonism (irrelevant in this stack)
- S-equol + isoliquiritigenin: ERβ preservation alongside fulvestrant
- Forskolin: 50mg/day, cAMP elevation, additive to CNP signaling
- HCG + HMG: LH/FSH maintenance throughout suppressive AAS stack
TIER 3 (SUPPORTING):
- IOX2: PHD2-selective HIF-1α stabilization in chondrocytes. Not DMOG.
- Epitalon/NA-Epitalon: telomerase activation in chondrocytes
- Cartalax: chondrocyte-specific cytoprotective
- BPC-157: GH receptor sensitization, connective tissue
- GHK-Cu, TB-500, KPV: growth plate microenvironment support
- TEPP-46: PKM2 tetrameric stabilization, glycolytic efficiency in hypoxic growth plate
MONITORING (non-optional):
Growth plate MRI every 3-4 months. Plate thickness is your primary feedback. Bloodwork for IGF-1, E2, LH/FSH, hematocrit every 4-6 weeks minimum.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Questions go below. I'll address things worth addressing.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
IX. AROMATASE INHIBITORS: WHICH ONE AND WHY IT MATTERS
Most people treat all AIs as interchangeable. They're not. The differences in mechanism, potency, BBB penetration, and reversibility have real practical consequences for this protocol specifically.
Anastrozole (non-steroidal, competitive, reversible)
Competitive inhibitor of aromatase — binds the enzyme and blocks it, but new substrate can displace it and the enzyme itself is not destroyed. Around 80-85% E2 suppression at 0.5-1mg/day. When you stop, aromatase activity restores quickly as the drug clears.
Key point: anastrozole does not cross the blood-brain barrier meaningfully. Brain aromatase remains active. The brain continues producing its own local E2 independently of systemic suppression. This is a feature, not a limitation.
Good for: primary AI use when you want systemic E2 suppression with minimal CNS impact. Dose 0.5mg EOD to 1mg/day depending on aromatizable substrate load in the stack.
Letrozole (non-steroidal, competitive, irreversible in practice)
Technically competitive but binds with such affinity it functionally behaves as irreversible. Destroys the enzyme permanently — new aromatase protein has to be synthesized. 98% E2 suppression at 2.5mg. Far more complete than anastrozole.
Key point: letrozole DOES cross the BBB. It suppresses brain aromatase in addition to systemic aromatase. This is where the cognitive concern is legitimate.
Key advantage: letrozole penetrates tissue better than anastrozole. This includes growth plate chondrocytes, which express local aromatase and produce their own E2 in situ. Anastrozole may not adequately suppress this local chondrocyte aromatization. Letrozole at therapeutic dose can reach avascular cartilage and block local E2 production at the actual target tissue.
Optimal use in this protocol: low-dose letrozole (0.25-0.5mg EOD, not full 2.5mg) stacked with anastrozole. You get letrozole's tissue penetration advantage without hammering brain aromatase at full dose. The anastrozole provides the systemic baseline coverage.
Exemestane (steroidal, suicidal/irreversible)
Mechanism-based irreversible inhibitor — binds the active site and permanently inactivates the enzyme through covalent modification. The steroidal structure means it has mild androgenic activity (can partially convert to androgenic metabolites). Around 85-95% E2 suppression.
BBB penetration is intermediate between anastrozole and letrozole. Less predictable tissue distribution. The androgenic metabolite angle is a mild positive in an androgenic stack context but not clinically meaningful.
Use case: good alternative if anastrozole tolerance is poor, or as a cycling option to prevent resistance development to any single AI mechanism. Less optimal than the anastrozole + low-dose letrozole combo for this protocol.
The optimal AI strategy for this protocol:
Anastrozole 0.5mg EOD as base coverage + low-dose letrozole 0.25mg EOD for tissue penetration into growth plate chondrocytes. Together they hit both systemic aromatization and local chondrocyte aromatization without the full-dose letrozole brain aromatase suppression problem. Fulvestrant or camizestrant then handles the ERα receptor itself regardless of residual local E2.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
X. DEBATE: "AROMATASE INHIBITORS CAUSE BRAIN DAMAGE FROM LOW E2"
Verdict: DOES NOT APPLY TO THIS PROTOCOL
This is a common argument and the data behind it is real. There are studies showing cognitive impairment in postmenopausal women on anastrozole, verbal memory deficits, processing speed reductions, and in longer studies structural changes. People then extrapolate: "running an AI will damage your brain."
Here is why that argument is essentially irrelevant in this specific protocol context.
Reason 1: Anastrozole does not cross the blood-brain barrier
The brain has its own aromatase. Neurons and glial cells synthesize estradiol locally, independently of circulating E2. Anastrozole's molecular properties (size, polarity, P-gp substrate status) result in very low CNS penetration. When you run anastrozole, systemic E2 drops but brain aromatase keeps running. The neurons that depend on local estradiol for neuroprotection, BDNF upregulation, synaptic plasticity, and myelination are largely unaffected because the enzyme producing their E2 is not being inhibited.
The women in the cognitive impairment studies had very low baseline E2 already (postmenopausal) and anastrozole was removing what little circulating E2 they had left, which their brains were partially dependent on. A completely different physiological context.
Reason 2: Fulvestrant does not cross the blood-brain barrier either
Fulvestrant is a large, highly lipophilic molecule that is a P-glycoprotein substrate. It is actively effluxed from CNS tissue. ERα at the brain is not meaningfully degraded by fulvestrant at systemic doses. The central ER signaling environment remains largely intact.
Reason 3: S-equol crosses the BBB and activates ERβ centrally
S-equol is a small molecule with around 20x selectivity for ERβ over ERα. It crosses the blood-brain barrier freely. In the CNS, ERβ is the primary mediator of estrogen's neuroprotective effects. ERβ activation in the brain drives BDNF expression, promotes neurogenesis, reduces neuroinflammation, and has antidepressant-like effects. Running S-equol alongside an AI means your brain's ERβ is being actively agonized even as systemic E2 drops.
Reason 4: Isoliquiritigenin crosses the BBB and hits multiple neuroprotective targets
Isoliquiritigenin is a flavonoid with ERβ selectivity that penetrates CNS tissue. It does the following in the brain independently:
- ERβ agonism (neuroprotective, same mechanism as S-equol but additive)
- NMDA receptor modulation (cognitive and memory relevant)
- Acetylcholinesterase inhibition (increases acetylcholine availability, directly pro-cognitive)
- BDNF pathway upregulation
This compound is not just covering estrogen-related brain protection. It's genuinely nootropic on multiple independent axes.
Reason 5: Letrozole brain risk is addressed by dose management
If running letrozole, the legitimate brain aromatase suppression concern is real because letro does cross the BBB. This is handled by running it at low dose (0.25mg EOD rather than 2.5mg/day) stacked with anastrozole rather than letro as a standalone. The tissue penetration benefit of letro is achieved at a dose that does not devastate brain aromatase while the S-equol + isoliquiritigenin layer provides ERβ coverage throughout.
The bottom line:
The "AI causes brain damage" argument applies to postmenopausal women running anastrozole alone with no CNS-active ERβ agonists and no local brain aromatase protection strategy. That is a completely different pharmacological scenario from running a selective peripheral AI while actively agonizing CNS ERβ with BBB-penetrant compounds. The people raising this concern are applying data from one context to an entirely different one. In this protocol, CNS estrogen signaling is maintained and in some respects augmented (ERβ specifically) even as systemic ERα-mediated fusion signaling is eliminated.
@Volksstaffel
I'm going to write the actual definitive thread on height optimization. Not the stuff you find on here about "take mk677 bro." I mean the real mechanistic stack, grounded in growth plate biology. 99% of you are either running nothing, running things that actively work against you, or running the right things in the wrong order. I'll address the common arguments directly with verdicts.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
I. WHY IGF-1 LR3 AND INCRELEX ARE COPE FOR HEIGHT
This is the most common mistake I see. Someone runs 200mcg IGF-1 LR3 a day thinking they're doing something for height. They're not.
The Core Problem:
Exogenous IGF-1 without GH's independent effects pushes chondrocytes straight into hypertrophic differentiation. The plate thickens but doesn't elongate. You're not growing, you're accelerating ossification.
The growth plate has two distinct cell populations: resting zone progenitors (gpSSCs) and proliferative zone chondrocytes. GH acts on BOTH. Here is the critical mechanism most people don't know:
Dual Effector Theory (Green et al.):
GH has a DIRECT effect on resting zone stem cell recruitment, independent of IGF-1. It's not just "GH makes the liver produce IGF-1." GH also directly binds GHRs on resting zone progenitors and drives them into the proliferative pool. This is the effect that pure exogenous IGF-1 cannot replicate.
When you inject IGF-1 LR3 without this upstream GHR activation:
- IGF-1R on chondrocytes gets saturated and drives cells toward hypertrophic differentiation
- Hypertrophic chondrocytes expand 5-10x in volume, mineralize, die, and get replaced by bone
- The plate appears active on MRI but you're burning through your chondrocyte reserve faster
- Longitudinal growth requires: GH direct resting zone activation + IGF-1 proliferative expansion + controlled hypertrophy
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
II. GH: THE MASTER PATHWAY
GH is non-negotiable. It's the central axis everything else plugs into. But there's nuance that most people running GH still miss.
The IGF-1 Saturation Ceiling is Real:
Hepatic GH receptors saturate around 8-12 IU for most people. Past that dose you're not getting meaningfully more IGF-1. You're getting insulin resistance, joint compression from water retention, mTOR-driven chondrocyte senescence, and cortisol dysregulation. None of which you want.
The mTOR point is the most important thing most GH-brained people miss. Very high IGF-1 signaling activates mTOR which pushes cells toward differentiation rather than self-renewal. You're simultaneously running compounds to maintain stem cell stemness while chronically supraphysiological IGF-1 works against them. 8 IU is the rational sweet spot.
Tresiba (Basal Insulin) dramatically amplifies your GH response.
Insulin upregulates hepatic GH receptor expression. So the same 8 IU GH produces significantly more IGF-1 when paired with basal insulin coverage. Tresiba also hits IGF-1R at the growth plate directly. Not just glucose management. A synergistic anabolic on your chondrocytes.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
III. FGFR3 INHIBITORS: REMOVING THE BRAKE
FGFR3 is the endogenous brake on chondrocyte proliferation. Gain-of-function mutations cause achondroplasia. Even wildtype FGFR3 exerts tonic inhibition on the proliferative zone. You want to suppress it.
1. TYRA-300 [S TIER]
Highly selective oral FGFR3 inhibitor, Phase II. Best oral bioavailability. Grey market accessible. Purpose-built to suppress FGFR3 with minimal FGFR1/2 bleedthrough.
2. LOXO-435 (LY3866288) [S TIER]
361-fold selectivity for FGFR3 over FGFR1. The most selective FGFR3 inhibitor that exists. Wildtype FGFR3 inhibition requires a fraction of the oncologic dose, estimated 10-30mg/day. No serious AE profile at low dose.
3. Navepegritide [A TIER]
CNP analog. Works via NPR-B independently of FGFR3, while also downregulating FGFR3-MAPK signaling. FDA approved 2026. Prescription only. The independent anabolic arm via NPR-B is fully functional in non-ACH individuals.
4. Vosoritide (BMN-111) [A TIER]
Earlier generation CNP analog. Same mechanism as navepegritide, daily SC vs weekly. Has appeared in grey markets.
5. Infigratinib [B TIER]
Oral pan-FGFR inhibitor with FGFR3 preference. Less selective than TYRA-300 or LOXO-435. Real FGFR1/2 off-target risk. Accessible.
6. Erdafitinib [B TIER]
Pan-FGFR inhibitor. Accessible but significant FGFR1-mediated hyperphosphatemia at therapeutic doses. Last resort.
Stacking FGFR3 inhibitors with CNP analogs:
They work at different nodes. TYRA-300/LOXO-435 block FGFR3 at the receptor (kinase inhibition). CNP analogs drive positive chondrocyte signaling through NPR-B independently AND suppress FGFR3-MAPK from downstream. Complementary, not redundant.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
IV. SERDs AND AIs: THE ESTROGEN STRATEGY
E2 has a dose-dependent dual role at the growth plate:
- Low E2: stimulates proliferative zone via both ERα and ERβ
- High E2: accelerates hypertrophic differentiation and drives fusion via ERα
- ERα is the fusion receptor. ERβ is the proliferation/survival receptor.
Fulvestrant (500mg/14 days):
Pure pan-ER degrader. Degrades both ERα and ERβ. Most complete ERα blockade. Growth plate penetration limited (highly lipophilic, 99% protein bound) which is both a limitation and partly a feature.
Camizestrant:
Oral SERD with complete ERα degradation, lower MW improving growth plate cartilage penetration. Mechanistically superior to fulvestrant for this specific application.
Anastrozole (0.5-1mg/day):
Aromatase inhibitor, reduces E2 synthesis upstream. AI + SERD together gives fuller coverage than either alone.
ERβ Protection with S-equol and Isoliquiritigenin:
S-equol has roughly 20x selectivity for ERβ over ERα. If ERβ agonists occupy the binding pocket before fulvestrant binds, ERβ is partially protected from degradation. You get ERα degraded + ERβ partially preserved. This is pharmacologically coherent.
Critical Point on Skeletal Maturation:
Every warning about androgens causing bone age advancement is from studies with normal E2 levels. The skeletal maturation was ERα-mediated, driven by residual E2. With anastrozole + SERD eliminating E2 and degrading ERα, the androgenic stack loses its skeletal maturation risk entirely. The 1963 Laron study on fluoxymesterone shows this directly: growth velocity increased in every treated subject, and bone age advancement was dose and E2 dependent.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
V. KY19382: THREE-NODE WNT COVERAGE
KY19382 is a small molecule that does two things simultaneously:
1. Blocks CXXC5-DVL interaction
CXXC5 gets upregulated during growth plate senescence, triggered by estrogen. It binds DVL to suppress Wnt/β-catenin signaling, resulting in growth plate closure. KY19382 blocks CXXC5 from binding DVL downstream.
2. Inhibits GSK3β
GSK3β phosphorylates β-catenin for degradation. Inhibiting it allows β-catenin to accumulate and activate Wnt target genes including chondroprogenitor expansion.
Three-node Wnt coverage stacked with a SERD:
- Camizestrant blocks estrogen → CXXC5 transcription (upstream)
- KY19382 blocks CXXC5 → DVL binding (downstream)
- KY19382 inhibits GSK3β → activates β-catenin (independent of CXXC5)
Hitting Wnt/β-catenin suppression at three completely separate nodes simultaneously.
KY19382 Dosing Note:
Mouse study: 0.1mg/kg IP. HED for 58kg = 0.47mg/day IP equivalent. Oral bioavailability is 16.74%, so oral dose needed = approximately 2.8mg/day. Running 6mg oral ED gives an effective absorbed dose of ~1mg, roughly 2x the mouse-equivalent. Probably fine given the compound's safety profile in the study, but start at 3mg and titrate.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
VI. ABALOPARATIDE: THE PTHrP AXIS
Abaloparatide is a synthetic 34-aa analog of PTHrP(1-34). It binds the RG conformation of PTH1R, driving anabolic signaling with less hypercalcemia than teriparatide due to lower affinity for the R0 conformation that mediates renal calcium reabsorption.
Why it matters for height:
PTHrP is an endogenous signal that keeps growth plate chondrocytes in the proliferative state. It is the downstream effector of the IHH/PTHrP negative feedback loop that governs how fast chondrocytes progress from proliferative to hypertrophic. More PTHrP signaling = chondrocytes stay proliferative longer before committing to hypertrophy.
Abaloparatide does this pharmacologically. The net effect is:
- Delays hypertrophic differentiation, expanding the proliferative pool
- Keeps the plate in a growth-competent state longer
- Directly compensates for the anti-hypertrophy pressure you need to maintain balanced elongation
The balance point abaloparatide helps manage:
Your protocol is heavily anti-hypertrophic by design (mocetinostat, low E2, TYRA-300). The risk is you suppress hypertrophy too completely and the plate thickens without actually producing longitudinal growth. Abaloparatide's role is subtler than just "delays hypertrophy." It maintains PTH1R signaling to keep the feedback loop intact so chondrocytes still eventually progress through hypertrophy in a controlled and orderly manner, just slower. It's a rate modulator, not a complete block.
Dosing and practical notes:
Approved dose for osteoporosis: 80mcg/day SC. For growth plate purposes the dose relationship is not established. Daily SC injection is the limitation. The 2-year black box warning (osteosarcoma risk from rodent studies at high doses) applies, so duration planning matters. Do not skip the 2-year ceiling.
Important: why continuous PTH1R agonism is not ideal
PTH1R desensitizes under continuous stimulation. Internalization and downregulation occur. This is why teriparatide is pulsatile (daily injection for peak/trough) rather than continuous infusion. Abaloparatide's daily SC injection protocol is designed around this intermittent pulsatile mechanism. Do not attempt to run it as continuous infusion chasing "more signal." You will get less effect, not more.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
VII. ANDROGENS: THE NUANCE EVERYONE GETS WRONG
AR signaling at the growth plate = pro-proliferative
ERα signaling at the growth plate = pro-fusion
You can run androgenic compounds in a zero-E2 environment and get the proliferative AR benefit with none of the fusion risk.
Halotestin (Fluoxymesterone) | 5-10mg/day
AR affinity roughly 8-10x testosterone. Does not aromatize. Most potent androgenic oral available. At 5mg, hepatotoxicity concern is dramatically reduced vs the competitive dosing the warnings were written around. With TUDCA/NAC you can extend duration significantly. Delivers the strongest AR-mediated chondrocyte proliferative signal without any E2 conversion risk.
Anavar (Oxandrolone) | 30-50mg/day
Mild DHT derivative. Does not aromatize. Note: at 10mg it contributes essentially nothing meaningful to this stack beyond tissue preservation. The growth plate-relevant dose starts at 30-50mg. If you're already running Halo, Mast, and Primo then Anavar is arguably redundant as a fourth androgen and can be dropped.
Masteron (Drostanolone) | 300-400mg/week
2-alpha methyl DHT. Cannot aromatize. Its anti-estrogenic mechanism is a weak ER antagonist at the receptor level (not primarily an aromatase inhibitor as commonly stated). In a near-zero E2 environment that distinction is irrelevant since there's minimal E2 for it to block anyway. Clean additive androgenic signal.
Primobolan (Methenolone) | 400-600mg/week
Low hepatotoxicity. Moderate AR potency. No aromatization. Immunomodulatory properties. Lowest side effect profile of any injectable androgen. Best choice for long-duration runs where you need sustained androgenic background.
Trenbolone | use with caution on this protocol
Does not aromatize (good for this stack). Strong IGF-1 upregulation, potent anti-catabolic via GR antagonism. However significant progestin activity (60% of progesterone at PR) which complicates the endocrine environment. The neurological side profile including sleep disruption is directly counterproductive on a protocol where natural GH pulsatility and sleep quality matter. Short pulses only, or exclude.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
VIII. FORSKOLIN: THE OVERLOOKED cAMP DRIVER
Forskolin directly activates adenylyl cyclase, elevating intracellular cAMP broadly:
- cAMP is the second messenger for CNP/NPR-B signaling (additive to navepegritide)
- cAMP activates PKA, phosphorylates CREB, upregulates chondrogenic gene expression
- cAMP signaling promotes PTHrP expression and delays hypertrophic differentiation
- Direct synergy with A2B adenosine receptor signaling at the growth plate
Cheap, accessible, hits a node nothing else in the stack directly targets. 25-50mg/day standardized to 10% forskolin.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
IX. DEBATES: WHO WAS CORRECT, WHO WAS WRONG, AND HOW TO USE IT
These are real arguments that have come up in this community. I will give my actual verdict on each with the mechanistic reasoning, and most importantly the practical optimization conclusion.
---
DEBATE 1: "IGF-1 LR3 is equivalent to GH for height"
Verdict: WRONG
The wrong argument: "GH just converts to IGF-1 anyway, so running IGF-1 LR3 directly is more efficient. Same effect, skip the liver step."
Why it's wrong: GH has a direct, IGF-1-independent effect on resting zone gpSSCs via GHR binding on those cells (dual effector theory). Exogenous IGF-1 without this upstream gpSSC recruitment simply saturates IGF-1R on proliferating chondrocytes and pushes them into hypertrophy faster. You're not running out of IGF-1 signal on 8 IU GH. You're running out of the resting zone recruitment signal that IGF-1 LR3 cannot provide.
Optimization conclusion: Run GH at 8 IU. Do not add IGF-1 LR3 or Increlex unless you have a documented reason to believe your IGF-1 levels are low despite adequate GH dose. Get bloodwork. If IGF-1 is mid-range on 8 IU GH, Tresiba (basal insulin) is a far better lever than exogenous IGF-1 because it sensitizes hepatic GH receptors and amplifies your GH-to-IGF-1 conversion without the ossification risk.
---
DEBATE 2: "More GH is always better, just run 30 IU"
Verdict: PARTIALLY CORRECT (with critical conditions)
The argument: "GH has direct effects on resting zone chondrocytes beyond IGF-1. More GH = more direct recruitment. So 30 IU gives growth that 8 IU can't."
Why it's partially correct: True that direct GHR effects on the growth plate continue scaling beyond the IGF-1 saturation point. GH does recruit resting zone cells through a mechanism independent of hepatic IGF-1 output.
Why the conclusion is wrong: At 30 IU you get aggressive insulin resistance that creates a hostile metabolic environment for chondrocytes. Chronic hyperglycemia and hyperinsulinemia impair growth plate function. You also get mTOR hyperactivation which pushes cells toward differentiation rather than self-renewal, directly opposing SAG21k and KY19382. Water retention compresses joint spaces. The cardiovascular load is real. And you're paying 3-4x the cost for marginal direct GHR benefit over 12-16 IU.
Optimization conclusion: 8 IU base with Tresiba amplification is smarter than jumping to 30 IU. If escalating, go to 12-16 IU maximum and manage the insulin resistance aggressively. Never run 30 IU long-term on a growth plate protocol where stem cell self-renewal is a priority.
---
DEBATE 3: "TYRA-300 depletes your resting zone and causes plates to fuse faster"
Verdict: PARTIALLY CORRECT MECHANISM, WRONG CONCLUSION
The argument (forum): Someone reported their plates fused faster after running TYRA-300. Mechanism proposed: FGFR3 inhibition removes the proliferative brake, chondrocytes cycle faster, resting zone gets exhausted sooner, plate closes.
Why the mechanism has biological plausibility: The resting zone pool is finite. Anything accelerating chondrocyte throughput rate theoretically consumes it faster. Not nonsense.
Why the anecdote proves nothing: N=1, no documented baseline plate status, no controlled variables. The rapid fusion observed after stopping TYRA-300 is far more consistent with rebound FGFR3 hyperactivation after removing the inhibitor, which actively promotes terminal differentiation. Stopping abruptly is worse than tapering.
Why the conclusion is still wrong in context: The resting zone depletion risk is real on TYRA-300 alone. It is completely countered by SAG21k (symmetric gpSSC self-renewal), APEX-51B (perichondrial progenitor recruitment into resting zone), and mocetinostat/ricolinostat (extends chondrocyte proliferative lifespan). The correct response to this argument is not to avoid TYRA-300 but to run the full resting zone protection stack alongside it.
Optimization conclusion: Do not run TYRA-300 as a standalone. It is a one piece of a circuit. Pair it with SAG21k for resting zone replenishment and mocetinostat for extending chondrocyte proliferative lifespan. If access to SAG21k is limited, cycle TYRA-300 (8 weeks on, 4 weeks off minimum) rather than running it continuously. Never hard stop. Taper over 2-3 weeks.
---
DEBATE 4: "Androgens cause bone age advancement and will close your plates"
Verdict: WRONG IN THIS CONTEXT
The argument: "Halo/Anavar/Primo all accelerate bone maturation. The prescribing info says so. Don't use androgens for height."
Why it's contextually wrong: Every study that shows androgens accelerating bone age was conducted in subjects with normal E2 physiology. The skeletal maturation effect was ERα-mediated, driven by residual estradiol still circulating and acting on ERα at the growth plate. It was not the androgen doing the fusing, it was the estrogen that the androgen was aromatizing into, or the background estrogen present regardless.
The 1963 Laron fluoxymesterone study is the key reference. Even in those normal-E2 subjects, the growth plate fusion risk was dose-dependent and related to estrogen exposure. Running halo in a zero-E2 environment where anastrozole and fulvestrant have eliminated aromatizable substrate and degraded ERα fundamentally changes the pharmacological context. The prescribing warning simply does not apply.
Optimization conclusion: Run an AI to eliminate E2 production. Run a SERD (camizestrant/fulvestrant) to degrade ERα directly. In that environment, androgenic compounds provide pure AR-mediated proliferative signaling at the growth plate with zero skeletal maturation risk. This is a feature of the complete protocol, not a loophole. Half the protocol is what makes the other half safe.
---
DEBATE 5: "Blocking all estrogen is bad for height because estrogen makes you grow"
Verdict: WRONG (dose-dependent nuance missed)
The argument: "Estrogen promotes chondrocyte proliferation. Blocking it will slow your growth velocity."
Why it's partially true: At low levels, E2 does stimulate proliferative zone activity via both ERα and ERβ. Growth velocity in aromatase-deficient males is maintained but sometimes slightly reduced compared to normal E2. This is real.
Why the conclusion is wrong: At high pubertal levels, E2 drives growth plate fusion via ERα. The question is whether you want the modest proliferative contribution of E2 at the cost of accelerated fusion. The answer is no, because you can replace that proliferative signal with GH, IGF-1, abaloparatide, FGFR3 inhibitors, and SAG21k without the fusion risk. You're not losing anything you can't cover with better tools. You're gaining permanent plate preservation.
Optimization conclusion: The approach is not "block all estrogen." It's "degrade ERα to block fusion while preserving ERβ for chondrocyte survival via S-equol/isoliquiritigenin." The distinction matters. The goal is selective ERα suppression, not total estrogen ablation. Run camizestrant (selective ERα degrader) rather than fulvestrant if possible since fulvestrant is pan-ER.
---
DEBATE 6: "SARMs are better than AAS for this protocol because they don't suppress the HPTA"
Verdict: WRONG
The argument: "Use SARMs for the androgenic signal at the growth plate without suppressing LH/FSH."
Why it's wrong: SARMs still suppress HPTA. AR signaling at the hypothalamus does not care whether the ligand is "tissue-selective" at peripheral tissues. The hypothalamus has AR. RAD140 actually suppresses HPTA more aggressively than Anavar at similar AR occupancy levels because of its potency at hypothalamic AR. The whole "selective" premise was always about muscle vs prostate, not about HPG axis sparing.
Optimization conclusion: Run HCG + HMG throughout the androgenic stack to maintain testicular function and spermatogenesis. This is a far more reliable solution than trying to find an AR agonist that doesn't suppress LH/FSH. The latter doesn't exist at any meaningful dose. Use classical AAS and manage the suppression directly.
---
DEBATE 7: "PHD inhibitors for HIF-1α stabilization but DMOG raises hematocrit"
Verdict: CORRECT CONCERN, WRONG COMPOUND CHOICE
The argument: "PHD inhibition stabilizes HIF-1α in chondrocytes which upregulates glycolytic machinery in the hypoxic growth plate. But DMOG will raise your hematocrit since PHD2 inhibition stabilizes HIF-2α which drives EPO upregulation."
Why the concern is correct: Completely right about DMOG. It's a pan-PHD inhibitor hitting PHD1/2/3. PHD2 is the primary regulator of both HIF-1α in chondrocytes AND HIF-2α systemically. DMOG will raise EPO and hematocrit. This is the same reason roxadustat (a pan-PHD inhibitor) is specifically used to treat CKD anemia. If you want PHD inhibition without the hematocrit issue, you need selectivity.
Optimization conclusion: IOX2 is PHD2-selective with significantly higher preference for PHD2 over PHD1 and PHD3. In chondrocytes, PHD2 is the dominant regulator of HIF-1α. IOX2 stabilizes HIF-1α locally in the growth plate without meaningful HIF-2α/EPO drive. The hematocrit concern largely disappears. IOX2 is what you should be running, not DMOG. DMOG is what roxadustat wishes it wasn't.
---
DEBATE 8: "Blocking all hypertrophy = maximum growth plate preservation = maximum height"
Verdict: WRONG — this is the most dangerous protocol mistake
The argument: More HDAC inhibition, more anti-hypertrophy compounds, lower the hypertrophy rate as far as possible.
Why it's completely wrong: Longitudinal growth is produced by hypertrophic chondrocytes. They expand 5-10x in volume and then get replaced by bone at the metaphyseal front. That replacement is what makes you taller. If you suppress hypertrophy completely, the proliferative zone fills up with non-progressing chondrocytes. The plate thickens on MRI. But you don't grow. You are producing chondrocytes that never differentiate and never contribute to height.
The protocol should slow hypertrophy relative to proliferation. Not stop it.
Optimization conclusion: The lever is mocetinostat dose. Use growth plate MRI as your throttle control:
- Plate getting THICKER over time = proliferation dominant, too little hypertrophy, lower mocetinostat
- Plate STABLE thickness = perfect balance of proliferation and hypertrophic progression, you are actively growing
- Plate getting THINNER = hypertrophy outpacing proliferation, increase mocetinostat
Get MRI every 3-4 months. Adjust mocetinostat dose accordingly. This is not optional if you want to run this protocol seriously.
---
DEBATE 9: "Masteron inhibits aromatase, that's its anti-estrogenic mechanism"
Verdict: PARTIALLY WRONG (someone actually corrected this correctly)
The argument initially: Masteron inhibits aromatase activity, reducing E2 production.
The correction (which was right): Masteron's primary anti-estrogenic mechanism is acting as a weak competitive antagonist at the estrogen receptor, not via meaningful aromatase inhibition. It doesn't significantly reduce aromatase enzyme activity. It competes with E2 at ERα binding sites, blunting transcriptional response without fully activating the receptor.
Why it doesn't change masteron's role in this protocol: In a near-zero E2 environment with anastrozole + SERD coverage, there's essentially nothing for masteron to antagonize at ERα anyway. The ERα receptors are being degraded by fulvestrant/camizestrant. Masteron's value in this stack is purely androgenic signaling through AR, not its anti-estrogenic effect. The mechanism debate is interesting but operationally irrelevant here.
Optimization conclusion: Don't use masteron for E2 control. You have an AI and a SERD for that. Use masteron for its clean non-aromatizing androgenic signal and nothing else.
---
DEBATE 10: "T3 will accelerate height gain by driving hypertrophic zone progression"
Verdict: WRONG FOR THIS PROTOCOL
The argument: T3 directly drives hypertrophic zone differentiation which is rate-limiting for longitudinal growth. Therefore T3 should accelerate height gain.
Why it's wrong for this specific protocol: T3 accelerates hypertrophic differentiation, burning through the proliferative pool faster. On a protocol that is already carefully managing the proliferation/hypertrophy balance, adding T3 tilts the ratio in the wrong direction. You end up consuming your chondrocyte reserve faster without a proportional benefit since you're already driving elongation via GH/IGF-1/abaloparatide. The net effect is shorter runway.
Optimization conclusion: Drop T3 from this protocol entirely. Thyroid function should be kept euthyroid, not pushed toward accelerated differentiation. If you have subclinical hypothyroidism, correct it to normal range. Do not run supraphysiological T3 while trying to maintain resting zone progenitor supply.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
X. COMPLETE STACK SUMMARY
TIER 1 (NON-NEGOTIABLE CORE):
- GH: 8 IU/day split dosing, pre-bed emphasis
- TYRA-300: selective FGFR3 inhibitor, removes proliferative brake
- Fulvestrant or Camizestrant: ERα degradation, blocks plate fusion signal
- Anastrozole: upstream E2 suppression complementing SERD
- KY19382: Wnt/β-catenin activation at three nodes (3mg start, titrate to 6mg oral)
- Abaloparatide: 80mcg/day SC, PTHrP axis activation, keeps chondrocytes proliferative, balances hypertrophic progression
- SAG21k: Smoothened agonist, IHH pathway, gpSSC symmetric self-renewal
- Tresiba (basal insulin): amplifies GH-to-IGF-1 conversion, direct chondrocyte anabolism
TIER 2 (HIGH VALUE ADDITIONS):
- Navepegritide or Vosoritide: CNP analog, NPR-B agonism, stacks with FGFR3 inhibitor
- LOXO-435: if accessible, stack with TYRA-300 for dual-node FGFR3 suppression
- Mocetinostat: HDAC1/2/3 inhibitor, SOX9 upregulation. HDAC4 MUST BE SPARED. Dose titrated against MRI thickness feedback
- Ricolinostat: HDAC6 inhibitor, primary cilia function, potentiates SAG21k
- Halotestin: 5-10mg/day, highest AR potency, zero aromatization
- Primobolan: long-duration clean androgenic base
- Masteron: additive androgenic signal, weak ER antagonism (irrelevant in this stack)
- S-equol + isoliquiritigenin: ERβ preservation alongside fulvestrant
- Forskolin: 50mg/day, cAMP elevation, additive to CNP signaling
- HCG + HMG: LH/FSH maintenance throughout suppressive AAS stack
TIER 3 (SUPPORTING):
- IOX2: PHD2-selective HIF-1α stabilization in chondrocytes. Not DMOG.
- Epitalon/NA-Epitalon: telomerase activation in chondrocytes
- Cartalax: chondrocyte-specific cytoprotective
- BPC-157: GH receptor sensitization, connective tissue
- GHK-Cu, TB-500, KPV: growth plate microenvironment support
- TEPP-46: PKM2 tetrameric stabilization, glycolytic efficiency in hypoxic growth plate
MONITORING (non-optional):
Growth plate MRI every 3-4 months. Plate thickness is your primary feedback. Bloodwork for IGF-1, E2, LH/FSH, hematocrit every 4-6 weeks minimum.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Questions go below. I'll address things worth addressing.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
IX. AROMATASE INHIBITORS: WHICH ONE AND WHY IT MATTERS
Most people treat all AIs as interchangeable. They're not. The differences in mechanism, potency, BBB penetration, and reversibility have real practical consequences for this protocol specifically.
Anastrozole (non-steroidal, competitive, reversible)
Competitive inhibitor of aromatase — binds the enzyme and blocks it, but new substrate can displace it and the enzyme itself is not destroyed. Around 80-85% E2 suppression at 0.5-1mg/day. When you stop, aromatase activity restores quickly as the drug clears.
Key point: anastrozole does not cross the blood-brain barrier meaningfully. Brain aromatase remains active. The brain continues producing its own local E2 independently of systemic suppression. This is a feature, not a limitation.
Good for: primary AI use when you want systemic E2 suppression with minimal CNS impact. Dose 0.5mg EOD to 1mg/day depending on aromatizable substrate load in the stack.
Letrozole (non-steroidal, competitive, irreversible in practice)
Technically competitive but binds with such affinity it functionally behaves as irreversible. Destroys the enzyme permanently — new aromatase protein has to be synthesized. 98% E2 suppression at 2.5mg. Far more complete than anastrozole.
Key point: letrozole DOES cross the BBB. It suppresses brain aromatase in addition to systemic aromatase. This is where the cognitive concern is legitimate.
Key advantage: letrozole penetrates tissue better than anastrozole. This includes growth plate chondrocytes, which express local aromatase and produce their own E2 in situ. Anastrozole may not adequately suppress this local chondrocyte aromatization. Letrozole at therapeutic dose can reach avascular cartilage and block local E2 production at the actual target tissue.
Optimal use in this protocol: low-dose letrozole (0.25-0.5mg EOD, not full 2.5mg) stacked with anastrozole. You get letrozole's tissue penetration advantage without hammering brain aromatase at full dose. The anastrozole provides the systemic baseline coverage.
Exemestane (steroidal, suicidal/irreversible)
Mechanism-based irreversible inhibitor — binds the active site and permanently inactivates the enzyme through covalent modification. The steroidal structure means it has mild androgenic activity (can partially convert to androgenic metabolites). Around 85-95% E2 suppression.
BBB penetration is intermediate between anastrozole and letrozole. Less predictable tissue distribution. The androgenic metabolite angle is a mild positive in an androgenic stack context but not clinically meaningful.
Use case: good alternative if anastrozole tolerance is poor, or as a cycling option to prevent resistance development to any single AI mechanism. Less optimal than the anastrozole + low-dose letrozole combo for this protocol.
The optimal AI strategy for this protocol:
Anastrozole 0.5mg EOD as base coverage + low-dose letrozole 0.25mg EOD for tissue penetration into growth plate chondrocytes. Together they hit both systemic aromatization and local chondrocyte aromatization without the full-dose letrozole brain aromatase suppression problem. Fulvestrant or camizestrant then handles the ERα receptor itself regardless of residual local E2.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
X. DEBATE: "AROMATASE INHIBITORS CAUSE BRAIN DAMAGE FROM LOW E2"
Verdict: DOES NOT APPLY TO THIS PROTOCOL
This is a common argument and the data behind it is real. There are studies showing cognitive impairment in postmenopausal women on anastrozole, verbal memory deficits, processing speed reductions, and in longer studies structural changes. People then extrapolate: "running an AI will damage your brain."
Here is why that argument is essentially irrelevant in this specific protocol context.
Reason 1: Anastrozole does not cross the blood-brain barrier
The brain has its own aromatase. Neurons and glial cells synthesize estradiol locally, independently of circulating E2. Anastrozole's molecular properties (size, polarity, P-gp substrate status) result in very low CNS penetration. When you run anastrozole, systemic E2 drops but brain aromatase keeps running. The neurons that depend on local estradiol for neuroprotection, BDNF upregulation, synaptic plasticity, and myelination are largely unaffected because the enzyme producing their E2 is not being inhibited.
The women in the cognitive impairment studies had very low baseline E2 already (postmenopausal) and anastrozole was removing what little circulating E2 they had left, which their brains were partially dependent on. A completely different physiological context.
Reason 2: Fulvestrant does not cross the blood-brain barrier either
Fulvestrant is a large, highly lipophilic molecule that is a P-glycoprotein substrate. It is actively effluxed from CNS tissue. ERα at the brain is not meaningfully degraded by fulvestrant at systemic doses. The central ER signaling environment remains largely intact.
Reason 3: S-equol crosses the BBB and activates ERβ centrally
S-equol is a small molecule with around 20x selectivity for ERβ over ERα. It crosses the blood-brain barrier freely. In the CNS, ERβ is the primary mediator of estrogen's neuroprotective effects. ERβ activation in the brain drives BDNF expression, promotes neurogenesis, reduces neuroinflammation, and has antidepressant-like effects. Running S-equol alongside an AI means your brain's ERβ is being actively agonized even as systemic E2 drops.
Reason 4: Isoliquiritigenin crosses the BBB and hits multiple neuroprotective targets
Isoliquiritigenin is a flavonoid with ERβ selectivity that penetrates CNS tissue. It does the following in the brain independently:
- ERβ agonism (neuroprotective, same mechanism as S-equol but additive)
- NMDA receptor modulation (cognitive and memory relevant)
- Acetylcholinesterase inhibition (increases acetylcholine availability, directly pro-cognitive)
- BDNF pathway upregulation
This compound is not just covering estrogen-related brain protection. It's genuinely nootropic on multiple independent axes.
Reason 5: Letrozole brain risk is addressed by dose management
If running letrozole, the legitimate brain aromatase suppression concern is real because letro does cross the BBB. This is handled by running it at low dose (0.25mg EOD rather than 2.5mg/day) stacked with anastrozole rather than letro as a standalone. The tissue penetration benefit of letro is achieved at a dose that does not devastate brain aromatase while the S-equol + isoliquiritigenin layer provides ERβ coverage throughout.
The bottom line:
The "AI causes brain damage" argument applies to postmenopausal women running anastrozole alone with no CNS-active ERβ agonists and no local brain aromatase protection strategy. That is a completely different pharmacological scenario from running a selective peripheral AI while actively agonizing CNS ERβ with BBB-penetrant compounds. The people raising this concern are applying data from one context to an entirely different one. In this protocol, CNS estrogen signaling is maintained and in some respects augmented (ERβ specifically) even as systemic ERα-mediated fusion signaling is eliminated.
@Volksstaffel
